A recombinant FVIII to prevent and control
bleeding in people with hemophilia A1
Novoeight®—designed to fit
into his world
Michael, 30 years old, lives with hemophilia A.
RELIABILIT Y
PURITY
POR TA B IL ITY
0
20
86 F
INHIBITORS
CONFIRMED1
One of the largest clinical trials with
no inhibitors confirmed in 213 PTPsa,b
UP TO
-NM FILTERS
4
Employs state-of-the-art
double nanofiltration
o
FOR 12
MONTHS1
Highest storage temperature
for the longest durationc
PTPs=previously treated patients.
Please see Prescribing Information for complete storage instructions.
Patients with previous inhibitors were excluded from the trial. Individuals with hemophilia A may develop
inhibitors to FVIII. Monitor patients taking Novoeight® for inhibitor formation.1
b
guardian™1: a multicenter, multinational, open-label, single-arm efficacy and safety trial in 150 patients
(aged 12 to 65 years) with severe hemophilia A on a prophylactic treatment regimen who were exposed to
turoctocog alfa for a mean of 85 exposure days (ranging from 11 to 172 exposure days), which corresponds
to approximately 6 months in the trial. 2
guardian™3: a multicenter, multinational, noncontrolled, open-label safety, efficacy, and pharmacokinetic
trial in 63 previously treated pediatric patients (aged 0 to 11 years) with hemophilia A in which patients were
exposed to turoctocog alfa for a mean of 60 exposure days (ranging from 20 to 104 exposure days), which
corresponds to approximately 4.5 months in the trial. 3
c
Compared with other recombinant FVIII products.5-7
a
Visit NovoeightPro.com today
to learn more.
Indications and Usage
Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention
of bleed